Jun Feng Wang

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.

Harbour Biomed Shanghai Co. Ltd. engages in the development of therapeutics for cancer, especially in immuno-oncology. The company is headquartered in Shanghai, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Harbour Biomed Shanghai Co. Ltd. engages in the development of therapeutics for cancer, especially in immuno-oncology. The company is headquartered in Shanghai, China.

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.

Harbour Biomed Shanghai Co. Ltd. engages in the development of therapeutics for cancer, especially in immuno-oncology. The company is headquartered in Shanghai, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Harbour Biomed Shanghai Co. Ltd. engages in the development of therapeutics for cancer, especially in immuno-oncology. The company is headquartered in Shanghai, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.

Harbour Biomed Shanghai Co. Ltd. engages in the development of therapeutics for cancer, especially in immuno-oncology. The company is headquartered in Shanghai, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.

Yeasen Biotechnology (Shanghai) Co., Ltd. engages in the research, development, production, and sales of molecular, protein, and cell biological reagents. Its products are used in life science research, diagnosis and testing, biomedicine, and other fields. The company was founded by Wei Hua, Huang on January 9, 2014 and is headquartered in Shanghai, China.